Richiedi una copia del documento: CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration : in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window

Captcha code
Annulla